ELITE PHARMACEUTICALS INC /NV/ Quarterly Entity Common Stock, Shares Outstanding from Q2 2011 to Q3 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Entity Common Stock, Shares Outstanding history and growth rate from Q2 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Entity Common Stock, Shares Outstanding for the quarter ending November 14, 2024 was 1.07B shares, a 5.36% increase year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 1.07B +54.4M +5.36% Nov 14, 2024 10-Q 2024-11-14
Q2 2024 1.07B +54.4M +5.36% Jun 26, 2024 10-K 2024-07-01
Q4 2023 1.02B +3.87M +0.38% Feb 14, 2024 10-Q 2024-02-14
Q3 2023 1.01B 0 0% Nov 14, 2023 10-Q 2023-11-14
Q2 2023 1.01B +2.63M +0.26% Jun 20, 2023 10-K/A 2023-07-31
Q4 2022 1.01B +2.63M +0.26% Feb 14, 2023 10-Q 2023-02-14
Q3 2022 1.01B Nov 14, 2022 10-Q 2022-11-14
Q2 2022 1.01B +2.11M +0.21% Jun 23, 2022 10-K 2022-06-29
Q4 2021 1.01B +2.11M +0.21% Feb 11, 2022 10-Q 2022-02-14
Q2 2021 1.01B +169M +20.1% Jun 7, 2021 10-K 2021-06-14
Q4 2020 1.01B +170M +20.3% Feb 11, 2021 10-Q 2021-02-16
Q3 2020 1.01B +176M +21.2% Nov 10, 2020 10-Q 2020-11-16
Q2 2020 840M +12M +1.45% Jun 24, 2020 10-K 2020-06-30
Q4 2019 839M +18.7M +2.28% Feb 4, 2020 10-Q 2020-02-10
Q3 2019 833M +13.4M +1.63% Nov 5, 2019 10-Q 2019-11-12
Q2 2019 828M +24.7M +3.08% Jun 7, 2019 10-K 2019-06-21
Q4 2018 821M +29M +3.66% Feb 6, 2019 10-Q 2019-02-11
Q3 2018 819M +30.7M +3.89% Nov 2, 2018 10-Q 2018-11-09
Q2 2018 804M +28.1M +3.62% Jun 7, 2018 10-K 2018-06-14
Q4 2017 792M -126M -13.8% Feb 2, 2018 10-Q 2018-02-09
Q3 2017 789M -117M -12.9% Nov 2, 2017 10-Q 2017-11-09
Q2 2017 776M +49.1M +6.75% Jun 7, 2017 10-K 2017-06-14
Q4 2016 918M +223M +32% Feb 1, 2017 10-Q 2017-02-09
Q3 2016 906M +221M +32.3% Nov 4, 2016 10-Q 2016-11-09
Q2 2016 726M +65.6M +9.92% Jun 7, 2016 10-K 2016-06-15
Q4 2015 695M Feb 4, 2016 10-Q 2016-02-09
Q3 2015 685M +88.1M +14.8% Nov 5, 2015 10-Q/A 2015-12-30
Q2 2015 661M +92.9M +16.4% Aug 3, 2015 10-Q/A 2015-12-30
Q3 2014 597M +88.7M +17.5% Nov 4, 2014 10-Q 2014-11-14
Q2 2014 568M +173M +44% Jun 20, 2014 10-K 2014-06-30
Q4 2013 618M +262M +73.4% Feb 3, 2014 10-Q 2015-02-17
Q3 2013 508M +158M +45% Nov 4, 2013 10-Q 2013-11-14
Q2 2013 395M +48.4M +14% Jun 13, 2013 10-K 2013-06-21
Q4 2012 357M +88.7M +33.1% Feb 6, 2013 10-Q 2013-02-14
Q3 2012 350M +88.2M +33.7% Nov 8, 2012 10-Q 2012-11-14
Q2 2012 346M +99.1M +40.1% Jun 22, 2012 10-K 2012-06-29
Q4 2011 268M Jan 30, 2012 10-Q 2012-02-14
Q3 2011 262M Oct 31, 2011 10-Q 2011-11-14
Q2 2011 247M Aug 10, 2011 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.